Nadia Cross | Advanced Research Assistant

This person is a member of Sanger Institute Alumni.

Cross, Nadia

Nadia is an advanced research assistant working under the supervision of Julian Rayner. Her current work utilises phenotyping assay platforms developed in the lab to help further our understanding of erythrocyte invasion.

I joined the Wellcome Trust Sanger Institute Malaria Programme in 2014. I currently work on a variety of assay platforms which enable us to analyse phentoypes and help us to further our understanding of erythrocyte invasion.

Previously I have worked at The Walter and Eliza Hall Institute of Medical Research in their Infection and Immunity Division and also at The Macfarlane Burnet Institute both in Melbourne, Australia. In my previous roles my research focused on leading candidate antigens of malaria such as MSP2 and AMA-1. Specifically I was involved in measuring immune responses in clinical trials and in population studies from malaria endemic areas. I hold a BSc (HONS) in Medical Biology from Brunel University.

Publications

  • Differences in affinity of monoclonal and naturally acquired polyclonal antibodies against Plasmodium falciparum merozoite antigens.

    Reddy SB, Anders RF, Cross N, Mueller I, Senn N et al.

    BMC microbiology 2015;15;133

  • Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines.

    Terheggen U, Drew DR, Hodder AN, Cross NJ, Mugyenyi CK et al.

    BMC medicine 2014;12;183

  • Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development.

    Richards JS, Arumugam TU, Reiling L, Healer J, Hodder AN et al.

    Journal of immunology (Baltimore, Md. : 1950) 2013;191;2;795-809

  • New insights into acquisition, boosting, and longevity of immunity to malaria in pregnant women.

    Fowkes FJ, McGready R, Cross NJ, Hommel M, Simpson JA et al.

    The Journal of infectious diseases 2012;206;10;1612-21

  • A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720.

    McCarthy JS, Marjason J, Elliott S, Fahey P, Bang G et al.

    PloS one 2011;6;9;e24413

Cross, Nadia